Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Home Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience Launches its Phase 2 Registration Trial for ABI-009PEComa
Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Read More
Dave Lennon, PhD
Antitumor activity of ABI-009 (nab-rapamycin) in combination with anti-PD1 antibody in a syngeneic mouse model of B16 melanoma
Weekly nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Results From AMPECT, An Open-Label Phase 2 Registration Trial With Independent Radiology Review
Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa
ABI-009 (nab-sirolimus) in Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa): Preliminary Efficacy, Safety, and Mutational Status from AMPECT, an Open-label Phase II Registration Trial

Comments

Comments are closed.